Importantly, MMP14 expression is upregulated in response to IL-6, a pro-inflammatory cytokine elevated in FSHD and proposed as both a disease biomarker and therapeutic target (80–82). Here, MMP14 is linked to facioscapulohumeral muscular dystrophy.